United States: FDA Issues Guidance On Expanded Access Use Of Investigational Drugs

Michael Werner is a Partner and Jennifer Nowak is an Associate in Holland & Knight's Washington D.C. office

HIGHLIGHTS:

  • The U.S. Food and Drug Administration (FDA) has issued three final guidance documents that address FDA's rules and regulations governing "expanded access" to investigational drugs.
  • The expanded access process is designed to facilitate the availability of unapproved new investigational treatment options to patients with serious or immediately life-threatening diseases or conditions who lack therapeutic alternatives.
  • The three guidance documents aim to provide clarification of these criteria to those seeking expanded access and to make the required application to FDA less burdensome for doctors and patients.

The U.S. Food and Drug Administration (FDA) issued three final guidance documents on June 2, 2016, that address FDA's rules and regulations governing "expanded access" to investigational drugs. The expanded access process – often referred to as "compassionate use" – is designed to facilitate the availability of unapproved new investigational treatment options to patients with serious or immediately life-threatening diseases or conditions who lack therapeutic alternatives.

While FDA has promulgated regulations governing the availability of unapproved drugs outside of clinical trials for treatment purposes, the issue has become even more salient as patients, physicians, life sciences companies and policy makers have expressed frustration with continuing difficulty in gaining access to certain drugs. Indeed, several legislative proposals intended to address this issue are pending in Congress. These guidance documents do not change current FDA regulations; rather, they are FDA's attempt to streamline the process, at least in part as a response to these developments.

Brief Background on Expanded Access

Under regulations issued in 2009, FDA may permit expanded access to an investigational new drug outside of a clinical investigation, or to an approved drug where availability is limited by a limited by a risk evaluation and mitigation strategy (REMS), for an individual patient when certain criteria are all met:

  • the patient to be treated has a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition
  • the potential patient benefit justifies the potential risks of the treatment use and those potential risks are not unreasonable in the context of the disease or condition to be treated
  • providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval of the expanded access use or otherwise compromise the potential development of the expanded access use1

Additionally:

  • the patient's physician must determine that the probable risk to the person from the investigational drug is not greater than the probable risk from the disease or condition
  • FDA must determine that the patient cannot obtain the investigational drug under another IND or protocol2

A subset of this type of expanded access is emergency expanded access for an individual patient. In an emergency situation that requires immediate treatment before a written submission to FDA can be made, FDA may grant expanded access by telephone or other rapid means of communication. The treating sponsor must then submit an expanded access application within 15 working days of the initial authorization.

The three guidance documents issued on June 2 aim to provide clarification of these criteria to those seeking expanded access and to make the required application to FDA less burdensome for doctors and patients.

FDA's Final Guidance Documents

The first guidance document, "Individual Patient Expanded Access Applications: Form FDA 3926," streamlines the process for physicians to request use of an investigational new drug to treat individual patients who have exhausted other treatment options, including for emergency use. In its guidance, FDA expresses concern that some physicians requesting expanded access for individual patients have encountered difficulty completing required documentation because the existing forms are not tailored to requests for individual patient expanded access.

The current Form 1571 is used by sponsors for all types of Investigational New Drug (IND) submissions, including for large clinical trials, while the new Form 3926 is designed specifically for individual patient expanded access requests.3 FDA anticipates that physicians will be able to complete the new form in 45 minutes. Form FDA 3926 may also be used for certain follow-up submissions to an individual patient expanded access IND, such as safety reports, changes to treatment plans and after-treatment summaries. The process for emergency use expanded access will not change, but the physician will use the new Form 3926 instead of Form 1571.

The guidance document also provides some clarification of existing requirements. FDA instructs that when a physician would like to obtain an investigational drug outside of a clinical investigation for an individual patient, the physician should first ensure that the investigational drug can be obtained. If so, the physician needs to obtain a Letter of Authorization (LOA) from the sponsor of the referenced IND (e.g., commercial sponsor or drug manufacturer). The LOA permits FDA to refer to information that the sponsor of the IND has submitted to FDA. In cases where it is not possible to obtain an LOA (e.g., the entity supplying the drug does not have an IND filed with FDA), FDA instructs the physician to contact the relevant review division at FDA to determine what information is needed to support the expanded access submission. Physicians should also contact the review division if the requested individual patient expanded access IND is for an approved drug for which availability is limited by a REMS. The physician should then submit an individual patient expanded access IND to the appropriate FDA review division and may choose to use Form FDA 3926.

The other two guidance documents do not provide new policies or processes but rather are designed to answer questions about FDA's broader expanded access program and provide more details regarding the rules governing charging for investigational drugs provided under early access programs or under other INDs.

In its "Expanded Access to Investigational Drugs for Treatment Use – Questions and Answers" guidance document, FDA responds to frequently asked questions about the entire expanded access program. The document addresses not only requests to FDA for individual patient expanded use under a new IND (i.e., requests under the new Form 3926) but also requests for individual patient expanded use under a new protocol to an existing IND, as well as expanded access for intermediate and large populations.

Highlights of common issues addressed in the guidance by FDA include:

  • clarifying the roles played by the patient, the treating physician, the FDA and the IND sponsor in making expanded access decisions.
  • explaining the difference between expanded use for individual patients under a new IND versus a protocol to an existing IND. A new IND is typically requested when the original IND sponsor does not wish to be the sponsor of the expanded access use. In this case, the physician acts as sponsor under the new expanded access IND.
  • clarifying that Institutional Review Board (IRB) approval and informed consent are required for expanded use submissions. For emergency expanded use, treatment may begin before IRB approval, but must be reported to an IRB within five days. Additionally, FDA recognizes in the document the competing concerns of ensuring IRB oversight and providing timely access to treatment for patients in need. FDA states that it has recommended the use of central IRBs for review of expanded access uses, but acknowledges that additional options may be needed.
  • outlining the timing for initiation of treatment under various expanded access approvals.
  • addressing complex situations such as the ability for a patient to be treated under more than one expanded access IND, or to be treated with multiple courses of therapy or treated for a chronic condition under an IND.

Finally, FDA issued "Charging for Investigational Drugs under an IND – Questions and Answers" to address common questions related to the implementation of FDA's regulations in such situations. This includes charging for expanded access use as well as clinical trial use. In 2009, FDA revised its 1987 regulations governing circumstances under which a sponsor may charge for investigational drugs. The 2009 revision was meant to address: 1) circumstances regarding charging for investigational drugs in a clinical trial that were not anticipated under the original rule, 2) criteria for charging under all categories of expanded aces, and 3) types of costs that can be recovered when charging under an IND. This guidance document provides additional clarification on the 2009 regulations, including the criteria for charging for an investigational drug, the process for seeking FDA approval to charge for the drug and allowable cost recovery calculations.

Footnotes

1. 21 C.F.R. §312.305(a).

2. 21 C.F.R. §312.310(a).

3. FDA intends to accept submission of a completed Form FDA 3926 to comply with the IND submission requirements in §§312.23, 312.305(b), and 312.310(b).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.